Acorda Therapeutics to Present at the Baird 2015 Healthcare Conference
September 03 2015 - 7:00AM
Business Wire
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Michael
Rogers, Chief Financial Officer, will present at the Baird 2015
Healthcare Conference in New York on Wednesday, September 9 at
2:00pm.
A live audio webcast of the presentation can be accessed under
“Investor Events” in the Investor section of the Acorda website at
www.acorda.com, or you may use the link:
http://wsw.com/webcast/baird43/acor
Please log in approximately 5 minutes before the scheduled time
of the presentations to ensure a timely connection. An archived
version of this webcast will be available until October 9, 2015 on
the Investors section of www.acorda.com.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biotechnology company
focused on developing therapies that restore function and improve
the lives of people with neurological disorders.
Acorda markets three FDA-approved therapies, including AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg. The Company has
one of the leading pipelines in the industry of novel neurological
therapies. Acorda is currently developing a number of clinical and
preclinical stage therapies. This pipeline addresses a range of
disorders including post-stroke walking deficits, Parkinson’s
disease, epilepsy, heart failure, MS and spinal cord injury.
For more information, please visit the Company’s website at:
www.acorda.com.
Forward Looking Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements, other than statements of historical facts,
regarding management's expectations, beliefs, goals, plans or
prospects should be considered forward-looking. These statements
are subject to risks and uncertainties that could cause actual
results to differ materially, including the ability to realize the
benefits anticipated from the Civitas transaction and to
successfully integrate Civitas' operations into our operations; our
ability to successfully market and sell Ampyra in the U.S.; third
party payers (including governmental agencies) may not reimburse
for the use of Ampyra or our other products at acceptable rates or
at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; the risk of unfavorable results
from future studies of Ampyra or from our other research and
development programs, including CVT-301, Plumiaz, or any other
acquired or in-licensed programs; we may not be able to complete
development of, obtain regulatory approval for, or successfully
market CVT-301, Plumiaz, or any other products under development;
we may need to raise additional funds to finance our expanded
operations and may not be able to do so on acceptable terms; the
occurrence of adverse safety events with our products; delays in
obtaining or failure to obtain regulatory approval of or to
successfully market Fampyra outside of the U.S. and our dependence
on our collaboration partner Biogen in connection therewith;
competition; failure to protect our intellectual property, to
defend against the intellectual property claims of others or to
obtain third party intellectual property licenses needed for the
commercialization of our products; and, failure to comply with
regulatory requirements could result in adverse action by
regulatory agencies.
These and other risks are described in greater
detail in Acorda Therapeutics' filings with the Securities and
Exchange Commission. Acorda may not actually achieve the goals or
plans described in its forward-looking statements, and investors
should not place undue reliance on these statements.
Forward-looking statements made in this release are made only as of
the date hereof, and Acorda disclaims any intent or obligation to
update any forward-looking statements as a result of developments
occurring after the date of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150903005134/en/
Acorda TherapeuticsFelicia Vonella,
914-326-5146fvonella@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024